Denali Therapeutics Inc.
Developing therapies for neurodegenerative diseases that cross the blood-brain barrier.
DNLI | NDAQ
Overview
Corporate Details
- ISIN(s):
- US24823R1059
- LEI:
- Country:
- United States of America
- Address:
- 161 OYSTER POINT BLVD., 94080 SOUTH SAN FRANCISCO
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapeutics to defeat neurodegenerative and lysosomal storage diseases. The company's scientific approach leverages deep expertise in genetics and the biological pathways underlying conditions such as Alzheimer's disease, Parkinson's disease, and ALS. A key focus is its portfolio of product candidates engineered to cross the blood-brain barrier, a significant challenge in treating neurological disorders. Denali advances its pipeline, which includes programs in various stages of preclinical and clinical development, through rigorous in-house research and strategic partnerships.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Denali Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Denali Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Denali Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
